Details

Autor(en) / Beteiligte

• Nishio, Naoki
• van den Berg, Nynke S
• van Keulen, Stan
• Martin, Brock A
• Fakurnejad, Shayan
• Teraphongphom, Nutte
• Chirita, Stefania U
• Oberhelman, Nicholas J
• Lu, Guolan
• Horton, Crista E
• Kaplan, Michael J
• Divi, Vasu
• Colevas, A Dimitrios
• Rosenthal, Eben L

Titel

Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer

Ist Teil von

• Nature communications, 2019-11, Vol.10 (1), p.5044-10, Article 5044

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Identification of lymph node (LN) metastasis is essential for staging of solid tumors, and as a result, surgeons focus on harvesting significant numbers of LNs during ablative procedures for pathological evaluation. Isolating those LNs most likely to harbor metastatic disease can allow for a more rigorous evaluation of fewer LNs. Here we evaluate the impact of a systemically injected, near-infrared fluorescently-labeled, tumor-targeting contrast agent, panitumumab-IRDye800CW, to facilitate the identification of metastatic LNs in the ex vivo setting for head and neck cancer patients. Molecular imaging demonstrates a significantly higher mean fluorescence signal in metastatic LNs compared to benign LNs in head and neck cancer patients undergoing an elective neck dissection. Molecular imaging to preselect at-risk LNs may thus allow a more rigorous examination of LNs and subsequently lead to improved prognostication than regular neck dissection.